Free tool
FAERS Monitor: Neoral
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050736 or its brand name (Neoral, Cyclosporine). Reports on generic versions are filed under their own applications.
Reports
71,471
Serious
65,437
92% of reports
Hospitalization
24,247
Death reported
13,460
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,115
- off label use8,353
- product use in unapproved indication4,122
- pyrexia3,717
- pneumonia2,869
- diarrhoea2,746
- condition aggravated2,649
- nausea2,525
- cytomegalovirus infection2,257
- fatigue2,098
- hypertension2,081
- renal impairment2,032
- pain2,026
- sepsis2,004
- headache1,997
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,339 |
| 2005 | 1,287 |
| 2006 | 1,416 |
| 2007 | 1,387 |
| 2008 | 2,313 |
| 2009 | 2,478 |
| 2010 | 2,263 |
| 2011 | 3,028 |
| 2012 | 2,467 |
| 2013 | 1,352 |
| 2014 | 1,556 |
| 2015 | 1,530 |
| 2016 | 1,826 |
| 2017 | 2,279 |
| 2018 | 2,692 |
| 2019 | 3,509 |
| 2020 | 4,673 |
| 2021 | 4,283 |
| 2022 | 5,861 |
| 2023 | 5,833 |
| 2024 | 7,165 |
| 2025 | 6,275 |
| 2026 | 4,647 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,982,688 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytomegalovirus infectionSignal | 2,257 | 46.1 | 44.1 | 86,061 |
| renal impairmentSignal | 2,032 | 7.3 | 7.0 | 10,759 |
| sepsisSignal | 2,004 | 5.4 | 5.1 | 7,023 |
| product use in unapproved indicationSignal | 4,122 | 5.0 | 4.8 | 12,966 |
| pyrexiaSignal | 3,717 | 3.2 | 3.1 | 5,601 |
| hypertensionSignal | 2,081 | 2.9 | 2.8 | 2,608 |
| off label useSignal | 8,353 | 2.8 | 2.8 | 10,174 |
| pneumoniaSignal | 2,869 | 2.6 | 2.5 | 2,897 |
| condition aggravatedSignal | 2,649 | 2.6 | 2.5 | 2,572 |
| drug ineffectiveSignal | 9,115 | 2.0 | 2.0 | 5,138 |
| diarrhoea | 2,746 | 1.3 | 1.2 | 144 |
| pain | 2,026 | 1.0 | 0.9 | 2 |
| nausea | 2,525 | 0.9 | 0.9 | 10 |
| headache | 1,997 | 0.9 | 0.9 | 9 |
| fatigue | 2,098 | 0.8 | 0.8 | 118 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.